---

Background: Finasteride, a 4-azasteroid compound, is a specific inhibitor of type P 5α-reductase that converts testosterone into 5α-dihydrotestosterone. In the present study, the effects of human dose of finasteride on the number of spermatogenic cells, seminiferous, prostatic and epididymal tubules diameter and thickness of mature NMRI mouse were investigated, both in in vivo and in vitro conditions. Material and methods: In this experimental study, in in vivo condition, 18 mature NMRI mice were divided into 3 groups of 6: control (without treatment), sham (treatment whit physiologic serum) and experimental (treatment with drug). Experimental group was received intraperitoneal injection of 5 mg/kg/day finasteride for 7 days. In in vitro condition, testes, prostates and epididyms of 18 mature NMRI mice were divided into 3 groups of 6: control (fixation with bouin without treatment), sham (treatment with physiologic serum) and experimental (treatment with 5 mg/kg/day of finasteride in culture media for 3 days). Data were analyzed using one way ANOVA and Tukey test by SPSS software. P- value< 0.05 was considered significant.
Results: In in vivo condition, treatment with finasteride did not cause significant reduction in the number of spermatogenic cells, seminiferous tubules diameter compared with control group. But, in in vitro condition, significant decrease was observed. In both conditions, the drug could cause significant decrease in prostatic tubules diameter and thickness compared with control group. Diameter and thickness of epididymis tubules were decreased just in in vitro condition.
Conclusion: Finasteride can act in long-term treatment, high doses and in in vitro condition better than other conditions.

---

Background: Current pharmacological and non-pharmacological   treatment strategies   for   prostate cancer may control disease progression and increase the survival rates of patients but decreased quality of life is the most important concern of existing medical interventions. Erection dysfunction and fatigue are the most prevalent adverse effects of therapeutic procedures which impair the quality of life of patients from psychological and physiological viewpoints. We aimed in the first part of this review to explain and compare the adverse health effects of different therapeutic interventions and the level of their health impartments  At the second part of this review we showed clinical evidence for  risks and benefits of oral Ginseng supplement regimens in different stages of prostate cancer.
Materials and methods: To achieve these goals, human evidence and published clinical trials without time limit from databases until the end of 2019 were collected and qualitatively analyzed.
Results: The results showed that oral consumption of ginseng can improve erectile dysfunction, reduce fatigue and ultimately improve the quality of life of patients, but the duration of treatment, interactions and possible side effects of this supplement should also be considered.
Conclusion: Because of the relative effectiveness of this compound in continuous and long-term use, the role of ginseng in improving other aspects of quality of life in patients with prostate cancer, increasing life expectancy and drug resistance are other unknown aspects of this issue which needs further investigation.